BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 22939017)

  • 1. Introducing human papillomavirus vaccines into the health system in South Africa.
    Botha MH; Dochez C
    Vaccine; 2012 Sep; 30 Suppl 3():C28-34. PubMed ID: 22939017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
    Schwarz TF
    Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
    Poljak M
    Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.
    Dunne EF; Datta SD; E Markowitz L
    Cancer; 2008 Nov; 113(10 Suppl):2995-3003. PubMed ID: 18980283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
    Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
    Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus, cervical cancer, and the vaccines.
    Tovar JM; Bazaldua OV; Vargas L; Reile E
    Postgrad Med; 2008 Jul; 120(2):79-84. PubMed ID: 18654072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
    Adams M; Jasani B; Fiander A
    Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparing for HPV vaccination in South Africa: key challenges and opinions.
    Harries J; Moodley J; Barone MA; Mall S; Sinanovic E
    Vaccine; 2009 Jan; 27(1):38-44. PubMed ID: 18977271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands.
    Boot HJ; Wallenburg I; de Melker HE; Mangen MJ; Gerritsen AA; van der Maas NA; Berkhof J; Meijer CJ; Kimman TG
    Vaccine; 2007 Aug; 25(33):6245-56. PubMed ID: 17630049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine.
    Monsonego J; Cortes J; Greppe C; Hampl M; Joura E; Singer A
    Vaccine; 2010 Nov; 28(51):8065-72. PubMed ID: 20971114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human papillomavirus vaccines: current issues & future.
    Kawana K; Yasugi T; Taketani Y
    Indian J Med Res; 2009 Sep; 130(3):341-7. PubMed ID: 19901444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan.
    Tay SK; Ngan HY; Chu TY; Cheung AN; Tay EH
    Vaccine; 2008 Aug; 26 Suppl 12():M60-70. PubMed ID: 18945415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.
    Goldstone SE; Vuocolo S
    Expert Rev Vaccines; 2012 Apr; 11(4):395-406. PubMed ID: 22551023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human papillomavirus (HPV) vaccines: a Canadian update.
    Foerster V; Murtagh J
    Issues Emerg Health Technol; 2007 Dec; (109):1-8. PubMed ID: 18062141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus.
    Broomall EM; Reynolds SM; Jacobson RM
    Postgrad Med; 2010 Mar; 122(2):121-9. PubMed ID: 20203463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Pappilomavirus (HPV) induced cancers and prevention by immunization.
    Khaliq SA; Shyum Naqvi SB; Fatima A
    Pak J Pharm Sci; 2012 Oct; 25(4):763-72. PubMed ID: 23009992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quadrivalent human papillomavirus vaccine.
    Barr E; Tamms G
    Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreasing risk: impact of HPV vaccination on outcomes.
    Hymel PA
    Am J Manag Care; 2006 Dec; 12(17 Suppl):S473-83. PubMed ID: 17203991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-licensure monitoring of HPV vaccine in the United States.
    Markowitz LE; Hariri S; Unger ER; Saraiya M; Datta SD; Dunne EF
    Vaccine; 2010 Jul; 28(30):4731-7. PubMed ID: 20188681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human papillomavirus: current status and issues of vaccination.
    Malik H; Khan FH; Ahsan H
    Arch Virol; 2014 Feb; 159(2):199-205. PubMed ID: 24022639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.